Global Growth Hormone Market Overview
Growth Hormone Market Size was valued at USD 2.02 billion in 2021 and is projected to grow from USD 2.40 billion in 2022 to USD 9.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.46% during the forecast period (2024 - 2030).Rising incidence of growth hormone deficiency, and the increasing awareness about endocrine disorders & the effectiveness of growth hormones are fueling the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Growth Hormone Market Trends
- Rising incidence of growth hormone deficiency boosts market growth
Cushing's syndrome, turner syndrome, down syndrome, Noonan syndrome, Russell-silver syndrome, Prader Willi syndrome, and others are the most common growth hormone disorders across the globe. For instance, in March 2019, according to the National Organization for Rare Disorders, in the US, turner syndrome affects approximately 1 female in 2,000 to 2,500 live female births and estimated that more than 70,000 women and girls have turner syndrome. Moreover, growth hormone deficiency is caused by structural pituitary disease or cranial irradiation and occurs in the context of additional features of hypopituitarism.
Moreover, early diagnosis of endocrine disorders such as Addison’s disease, Cushing’s disease, graves' disease, Hashimoto thyroiditis, hyperthyroidism/hypothyroidism, prolactinoma, and others can substantially improve the chances of successful treatment and prevent severe complications. The government and various international organizations have launched a number of initiatives to raise awareness about early diagnosis. For instance, The International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a US-based nonprofit charitable organization, celebrates International Children’s Growth Awareness Day every year to spread awareness about the early diagnosis and treatment of growth hormone deficiency.
Growth Hormone Market Segment Insights
Growth Hormone Brand Insights
The growth hormone market segmentation, based on brand, includes Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, Skytrofa, and others. The Norditropin segment held the largest market in 2021 reaching a market value of USD 3.46 billion by 2030. The Skytrofa segment is expected to register the highest CAGR of 11.37% from 2022 to 2030. This is owing to the growing occurrences of growth hormone deficiency diseases, and technological advances, such as recombinant DNA technology, which is anticipated to fuel the growth of the segment. Moreover, Novo Nordisk’s (Denmark) Norditropin HGH injections are conveniently preloaded pen systems that are premixed and prefilled. The market share for this brand is attributed to the brand value, product quality, convenience, and simplicity of administration. Furthermore, Norditropin is convenient to store while traveling as it does not require refrigeration after activation, which increases its preference among patients.
August 2021: Ascendis Pharma A/S (Denmark) has received the US Food and Drug Administration (FDA) approval for SKYTROFA (lonapegsomatropin-tcgd) for treating pediatric patients aged one year and older.
Growth Hormone Route of Administration Insights
The growth hormone market segmentation, based on route of administration, includes subcutaneous, intramuscular, and intravenous. The subcutaneous segment held the largest market in 2021, and the intramuscular segment is expected to register the highest CAGR from 2024 to 2030. The growth of the subcutaneous segment is increasing as it leads to a significant rise in growth rates in patients and a low incidence of antibody development. The majority of GHD drugs are administered through the subcutaneous route of administration. For instance, brands such as Norditropin, Genotropin, Humatrope, Omnitrope, Nutropin, and Saizen are administered subcutaneously. This route of administration injection is reported to be less painful and easier to self-administer. It is also preferred in children and adults, eventually by means of easy-to-use pen-type delivery devices. Moreover, the subcutaneous route is highly preferred for chronic growth hormone therapy.
Growth Hormone Application Insights
The growth hormone market data has been segmented by application into pediatric growth hormone deficiency, adult growth hormone deficiency, idiopathic growth hormone deficiency, small for gestational age, turner syndrome, Prader Willi syndrome, and others. The pediatric growth hormone deficiency segment dominated the market in 2021 and small for gestational age is projected to be the faster-growing segment during the forecast period, 2022-2030. Growth hormone deficiency is an endocrine disorder characterized by the low secretion of growth hormones. The market share for the growth hormone deficiency segment is due to the growing prevalence of GHD, increasing penetration of drugs by prominent market players, and increasing awareness about the disease. Moreover, an increasing engagement of major market players in the development of growth hormone products is likely to drive market growth.
June 2021: Novo Nordisk A/S (Denmark) received approval from the US Food and Drug Administration for Wegovy for chronic weight management.
Figure 2: Growth Hormone Market, by Application, 2023 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Growth Hormone Distribution Channel Insights
Based on distribution channel, the growth hormone industry has been segmented into hospital pharmacies, retail pharmacies, online pharmacy, and specialty pharmacy. The hospital pharmacies segment dominated the market in 2021, while online pharmacy is projected to be the fastest-growing segment during the forecast period. Moreover, hospital pharmacies are preferred the synthetic or recombinant variants of growth hormone and the ease of availability. In addition, recombinant growth hormone is a prescription medication made available only with a prescription from a physician. Moreover, most hospitals have a policy that patients ought to buy medications prescribed by the practitioners from their premises only.
Growth Hormone Regional Insights
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America growth hormone market accounted for USD 1.76 billion in 2021 and is expected to exhibit an 10.02% CAGR during the study period. North America accounted for the largest market share due to the surging availability of novel drugs, backed by the existence of a high number of renowned firms and supportive reimbursement policies. Moreover, significant government efforts, a well-developed healthcare infrastructure, and a high level of awareness among people is driving the regional market growth during the forecast period.
Further, the major countries studied are: The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: GROWTH HORMONE MARKET SHARE BY REGION 2021 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe growth hormone market accounts for the second-largest market share due to the increased burden of growth hormone deficiencies, the rising availability of artificial growth hormones, and extensive R&D activities. The burden of growth hormone deficiency is rising in Europe due to stress, improper sleep and low glucose levels among people. For instance, in 2018, according to the European Medicines Agency, growth hormone deficiency affected around 4.7 in 10,000 people in the European Union (EU). Furthermore, the Germany Growth Hormone Market held the largest market share, and the France Growth Hormone Market was the fastest growing market in the Europe region.
The Asia-Pacific Growth Hormone Market is expected to grow at a CAGR of 11.26% from 2024 to 2030. This is due to factors such as penetration of vendors, and a rise in disposable income. Moreover, a surge in drug approvals and the frequent launch of new products also drive market growth. Moreover, China Growth Hormone Market held the largest market share, and the India Growth Hormone Market was the fastest growing market in the Asia-Pacific region.
Growth Hormone Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the growth hormone market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the growth hormone industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
Novo Nordisk A/S (Denmark) is a Danish pharmaceutical company that discovers, manufactures, and commercializes pharmaceutical products. The company's operating segments are diabetes, hemophilia, growth disorders, obesity, and other biopharmaceuticals. It has a strong clinical pipeline of drugs for type 1 diabetes, type 2 diabetes, obesity, atherosclerosis, hemophilia, and growth disorders. For instance, in September 2020, the FDA has approved Novo Nordisk's long-acting human growth hormone, Sogroya (Somapacitan). It's the first of the company's regulatory filings for the medicine, also submitted in the EU and Japan, to win approval.
Additionally, Pfizer Inc. (US) is a leading research-based biopharmaceutical company applying science and resources to inventive treatments that extend and significantly improve lives. Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For instance, in February 2020, Pfizer Inc. and OPKO's (US) Once-Weekly NGENLA (somatrogon) injection received marketing authorization by European Union for the treatment of pediatric growth hormone deficiency.
Key Companies in the Growth Hormone Market includes
- Novo Nordisk A/S (Denmark)
- Pfizer Inc. (US)
- Ascendis Pharma A/S (Denmark)
- EMD Serono (US)
- Ferring B.V. (Switzerland)
- Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China)
- Sandoz International GmbH (Germany)
- AnkeBio Co., Ltd (China)
- Ipsen Pharma (France)
- Genentech (US), among others
Growth Hormone Industry Developments
January 2022: Ascendis Pharma A/S (Denmark) received the European Commission's approval for TransCon hGH for paediatric growth hormone deficiency. TransCon hGH contains somatropin, which is used for paediatric patients diagnosed with growth hormone deficiency.
January 2018: Ferring B.V. (Switzerland) recieved approval from US Food Drug and Administration for ZOMACTON injection recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency.
March 2022: Ipsen Pharma (France) announced the investment in a new state-of-the-art electronic autoinjector for Somatuline Autogel/Somatuline Depot (lanreotide). This product is specifically designed to improve administration and the injection experience for patients.
Growth Hormone Market Segmentation
Growth Hormone Brand Outlook
-
Norditropin
-
Genotropin
-
Humatrope
-
Saizen
-
Omnitrope
-
Skytrofa
-
Others
Growth Hormone Route of Administration Outlook
-
Subcutaneous
-
Intramuscular
-
Intravenous
Growth Hormone Application Outlook
-
Pediatric Growth Hormone Deficiency
-
Adult Growth Hormone Deficiency
-
Idiopathic Growth Hormone Deficiency
-
Small for Gestational Age
-
Turner Syndrome
-
Prader-Willi Syndrome
-
Others
Growth Hormone Distribution Channel Outlook
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacy
-
Specialty Pharmacy
Growth Hormone Regional Outlook
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
| Report Attribute/Metric |
Details |
| Market Size 2021 |
USD 2.02 billion |
| Market Size 2022 |
USD 2.40 billion |
| Market Size 2030 |
USD 9.46 billion |
| Compound Annual Growth Rate (CAGR) |
9.46% (2024-2030) |
| Base Year |
2023 |
| Forecast Period |
2024-2030 |
| Historical Data |
2018 & 2020 |
| Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Brand, Route of Administration, Application, Distribution Channel, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered |
The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Novo Nordisk A/S (Denmark), Pfizer Inc. (US), Ascendis Pharma A/S (Denmark), EMD Serono (US), Ferring B.V. (Switzerland‎), Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China), Sandoz International GmbH (Germany), AnkeBio Co., Ltd (China), Ipsen Pharma (France), Genentech (US), and Others |
| Key Market Opportunities |
Increasing number of new product approvals and strategic collaborations among market players |
| Key Market Dynamics |
Increasing awareness about endocrine disorders and effectiveness of growth hormones Rising incidence of growth hormone deficiency |
Human Growth Hormone Market Highlights:
Frequently Asked Questions (FAQ) :
The growth hormone market is anticipated to reach 9.46 billion at a CAGR of 9.46% during the forecast period of 2024-2030
The US is expected to hold a 35-40% share of the market for growth hormone market during the forecast period of 2024-2030.
The growth hormone market is expected to grow at a 9.46% CAGR during the forecast period from 2024 to 2030.
The North America region market held the largest market share.
The key players include Novo Nordisk A/S (Denmark), Pfizer Inc. (US), Ascendis Pharma A/S (Denmark), EMD Serono (US), Ferring B.V. (Switzerland), Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China), Pfizer Inc. (US), Sandoz International GmbH (Germany), AnkeBio Co., Ltd (China), Ipsen Pharma (France), and Others.
The Norditropin brand led the growth hormone market.
Pediatric growth hormone deficiency had the largest market share.
